Michael Wechsler

The Evolving Role of Biologics and TSLP Inhibition in Severe Asthma and Upper Airway Disease - Episode 15 Published on: , , , Patients taper their own inhalers, and payers approve on exacerbations alone. The panel closes on where the evidence runs out and where documentation and advocacy take over. This episode, "Tapering Inhalers and Initiating Biologics Earlier in Severe Asthma," features the panel closing on two unresolved practical questions.

In "Selecting a Biologic in Severe Asthma: Biomarkers, Comorbidities, and Payers," our experts turn to the decision every clinician faces once the diagnosis is settled. Dr. Chupp asks Dr. Hanania whether anti-TSLP availability has shifted him toward using an anti-alarmin first, given trial data showing efficacy across the spectrum without requiring a biomarker, and whether he considers combination therapy or overlapping agents when switching. Dr. Hanania says the choice remains multifactorial.

This episode, "Remission in Severe Asthma: Aligning Physician Goals with Patient Goals," features the panel setting the practical issues aside to ask what success looks like. Dr. Chupp reframes the discussion around the patient. The goal is no longer stopping exacerbations; it is remission. He imagines patients on an injection monthly or every six months with only a rescue inhaler, rather than stacking inhaled therapies plus a biologic just to avoid prednisone twice a year.